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Calf  diarrhea is a common disease in young animals and the primary cause of  productivity 
and economic losses to cattle producers worldwide. According to the report from the 
National Animal Health Monitoring System for U.S. dairy, more than fi fty percent 
of  the deaths of  un-weaned calves is attributed to severe diarrhea. Enterotoxigenic 
Escherichia coli (ETEC) strain K99+ remains the most common pathogen isolated from 
calves which are younger than three days of  age. Dam vaccination and the use of  anti-
microbials remain the most used prophylactic and treatment options for calf  diarrhea. 
The rise in antibiotic resistance around the world has been a major concern and new 
alternative therapies have been explored. Mycobacterium Cell Wall Fraction (MCWF) is 
a biological immunomodulator that has a potential in multiple veterinary health services 
such as the treatment and prevention of  infectious diseases and anticancer therapy 
in both small and large animals. The effi cacy of  the MCWF in reducing the severity 
of  neonatal calf  diarrhea and its associated mortality, following challenge with ETEC 
K99+ was evaluated. Twenty-three calves were placed into two experimental groups. 
Eleven calves received a single 1 mL dose of  MCWF intravenously (IV) at the onset of  
clinical signs of  disease following challenge. Twelve non-treated, challenged calves were 
retained as controls. The severity and duration of  diarrhea was signifi cantly reduced in 
the MCWF treated group compared to untreated controls. In addition, the mortality 
rate in the MCWF treated group was signifi cantly reduced to 10% while the observed 
mortality in the control group reached 58%. Data from the current study suggest that 
MCWF could be used as an alternative treatment to reduce the severity, duration and 
mortality of  ETEC induced diarrhea in neonatal calves. 
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INTRODUCTION
Calf  diarrhea remains the major cause of  economic losses to cattle producers around 
the world. In the United States (US), the National Animal Health Monitoring System 
(NAHMS) for dairy operations USDA [1], reported that diarrhea was responsible 
for 57% of  pre-weaned calf  mortality, observed mostly in calves younger than one 
month of  age. While the cattle industry has gone to great measures to improve 
herd management, animal facilities, feeding and nutrition, and the appropriate use 
of  bio-pharmaceuticals, calf  diarrhea still remains a problem due to its multifaceted 
nature [2]. Prevention and control strategies of  diarrhea in young calves is based on a 
proper understanding of  the disease complexities: multiple pathogens, co-infections, 
environmental factors, feeding and management during the calving period [3].  In 
cattle, due to the presence of  epitheliochorial placenta [4] transplacental transfer of  
immunoglobulins does not occur. Therefore, the neonate is highly dependent on the 
passive transfer of  immunoglobulins through the colostrum. The primary function 
of  colostrum is to enhance the calf ’s immune system through the passive transfer of  
both antibody and cell-mediated immune components particularly within the fi rst 6-18 
hours of  the calf ’s life [5]. Failure to obtain colostrum predisposes the neonate to the 
development of  disease [6]. It has been documented that Escherichia coli, although part 
of  the normal microbiota of  the gastrointestinal tract (GIT), can also be associated 
with a variety of  pathological conditions in newborn calves [7]. Enterotoxigenic E. 
coli (ETEC) possessing the F5 (K99) fi mbrial adhesin [8] and producing heat-stable 
enterotoxin [9], is the most common pathogen causing moderate to severe diarrhea 
and mortality in one to three days old calves. In addition, other enteropathogens known 
as a common cause of  diarrhea in calves under one month of  age are Coronavirus, 
Cryptosporidium parvum, Rotavirus and Clostridium perfringens [10-12].
Current preventive strategies for neonatal diarrhea in calves include the metaphylactic 
use of  antibiotics, anti-E. coli monoclonal antibodies enriched colostrum and fl uid 
therapies. Commercial multivalent vaccines are available for use in healthy pregnant 
heifers and cows as an aid in the prevention of  neonatal calf  diarrhea [13,14]. These 
vaccines stimulate the production of  protective antibodies that are present in the dam’s 
colostrum; however, the disadvantage of  this approach is that due to variations in 
farm management not all calves receive a suffi cient quantity of  colostrum, or any at all 
particularly in the veal industry.  The main disadvantage for the use of  antibiotics as a 
preventive and uncontrolled treatment measure is the increasing concern for antibiotic 
resistance, which could potentially lead to the development of  novel pathogenic 
strains that may have a signifi cant negative impact on both animal and human health. 
Therefore, the focus of  current research in the fi eld of  large animal veterinary science is 
on the development of  novel natural and biologically related products, such as immune 
response modifi ers [immunomodulators] which could signifi cantly improve the health 
status of  animals and reduce the need for antibiotic use [15,16].  The Mycobacterium 
Cell Wall Fraction (MCWF) is a biological immunomodulator derived from non-
pathogenic Mycobacterium phlei. MCWF has potential use in multiple veterinary health 
services, such as the treatment of  infectious diseases [17] and in anticancer therapy 
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[18]. The mode of  action of  MCWF is based on the activation of  innate and adaptive 
(humoral and cell-mediated) immunity with the purpose of  recognition, reaction to 
and recovery from infections. In the current study, we demonstrated the effi cacy 
of  the commercially available formulation MCWF (Amplimune™, NovaVive Inc., 
Belleville, Ontario, Canada) as an immunostimulant to reduce the severity of  diarrhea 
and its associated mortality in neonatal calves infected with ETEC K99+.
MATERIALS AND METHODS
Description of test animals
Twenty-three, newborn, clinically healthy, male, colostrum-deprived Holstein calves 
were purchased from multiple local dairy farms within four hours of  birth and 
transported to the Bioniche research facility at Putnam, Ontario, Canada. On arrival 
at the research farm, a whole blood sample was collected from each calf  and the zinc 
sulphate turbidity test (ZST) was performed (on arrival and 48 hours later) to confi rm 
that a transfer of  maternal antibodies had not occurred. Each calf  was identifi ed with 
an all-fl ex ear tag marked with a unique identifi cation number. The same identifi cation 
number was assigned to the corresponding blood and serum samples. Calves were 
housed in individual pens bedded with straw, within an open shelter that prevented 
direct contact with other animals. Each pen was cleaned daily and disinfected between 
calves. Calves were fed three times daily with a milk replacer. No other medications or 
vaccinations, except for the tested product, were administered throughout the study 
period. 
Mycobacterium cell wall fraction (MCWF) immunostimulant
Mycobacterium Cell Wall Fraction Immunostimulant (Serial Number 910707A) was 
manufactured according to the current outline of  production fi led with the USDA as 
product code 9300.02. The trade name of  this product, currently registered in the USA 
and Canada, is Amplimune™ and contains purifi ed MCWF, and squalane emulsifi ed 
in phosphate-buffered saline (PBS) solution.. Amplimune™, is manufactured at 
NovaVive USA Inc., Athens, Georgia, U.S.A. The recommended label dose of  1 mL 
intravenously was used in the current study.
Experimental design
The study was randomized, controlled and blinded. The veterinary technician 
administering the MCWF treatment was not involved in data collection. A designated 
veterinarian performing clinical scoring and data collection was blinded to the 
experimental groups. The principal investigator and personnel performing laboratory 
testing and statistical analysis were also blinded to the experimental groups. All 
procedures were designed in accordance with the Canadian Council on Animal Care 
(CCAC) guidelines. The test facility was a registered research facility under the Animals 
for Research Act, Ontario Ministry of  Agriculture and Food and was also accredited 
in Good Animal Practices by the CCAC. In order to ensure compliance, the study 
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protocol (AUP# 0401-1979) was reviewed and approved by the test facility’s Animal 
Care Committee before the start of  the trial. Twenty-three calves were used for the 
purpose of  the study and placed into two experimental groups. A random allocation 
chart was prepared in advance using the random function in Excel statistical software 
(Microsoft, CA, USA) to determine which group each calf  was assigned to. The 
designated treatment injection site was the jugular vein on the left side of  the neck. All 
blood samples were collected from the right jugular vein to ensure that any reactions 
at the site of  injection were specifi c to MCWF. Eleven calves were assigned to group 1 
and received a single 1 mL dose of  MCWF intravenously (IV) at the onset of  clinical 
signs of  disease (diarrhea) following challenge. Following challenge and disease onset, 
calves were not treated with antibiotics. Calves were observed for seven days following 
challenge. One calf  from the MCWF group was removed from the study, at 36 hours 
after birth, due to an umbilical cord infection and the collected data were not analyzed.
Challenge culture and treatment procedure
The ETEC culture was obtained from Dr. David Francis, South Dakota State 
Veterinary Diagnostic Laboratory, Brookings, SD. After confi rmation of  its purity 
and the presence of  K99 pili, the culture was expanded and lyophilized. A fresh 
challenge culture was started every eight hours during the calf  challenge period by 
growing the bacteria for 12 hours at 37°C in Minca broth in a shake fl ask. Only fresh 
cultures less than 12 hours old were used to challenge the calves. The culture was 
diluted to a standardized optical density (OD) of  0.2 just prior to challenge. Viable 
counts of  each challenge dose were performed to confi rm the number of  pathogenic 
microorganisms. The target challenge dose was 2 x 109 colony forming units (CFU). 
Each calf  was administered an oral dose of  20 mL of  challenge culture containing 2 x 
109 CFU diluted in 250 mL of  milk replacer.  The average age of  the calves at the time 
of  challenge was 5.6 and 7.8 hours for the control and MCWF groups, respectively. 
Ten calves in group 1 were treated with one IV dose (1 mL) of  MCWF product 
when the fi rst clinical signs of  diarrhea were observed (18-24 hours post challenge). 
Following MCWF administration, the calves were closely monitored two hours for 
the occurrence of  any systemic or local adverse reactions. A fecal sample from each 
calf  was collected at the onset of  clinical signs and subjected to microbiological 
confi rmatory testing for the presence of  E.coli K99+.
Clinical observations
Each calf ’s vital signs were recorded immediately upon arrival at the research facility 
and prior to challenge by the designated clinical veterinarian. Following challenge, 
and during the seven-day course of  the study, each calf  was further monitored three 
times per day at feeding times and records of  body temperature, fecal consistency, 
behavior, milk consumption, hydration and body weight were collected. Clinical scores 
for behavior, milk consumption, and fecal consistency were scored on a scale of  0 
(normal) to 3 (severe symptoms) and dehydration was scored on a scale of  0 (normal) 
to 2 (severe dehydration) (Table 1). Calves were weighed on arrival, prior to each 
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morning feeding and at the time of  death or euthanasia and body scores were assigned 
daily according to the total body weight loss (Table 1). The injection site was shaved in 
both groups to maintain the blind status and observed daily for any signs of  swelling, 
induration or pain.
Due to the animal welfare considerations and as per guidance from United States 
Department of  Agriculture (1) and Canadian Food Inspection Agency (CFIA) the 
supportive I.V fl uid therapy was applied (Calf-lyte) when a combination of  dehydration 
score of  2 and fecal and behavior score of  3 were observed. If  same clinical scores were 
observed for two consecutive days animals were humanely euthanized by intravenous 
administration of  barbiturate (80 mg/kg sodium pentobarbital). Any calf  that died 
during the course of  the study was necropsied and fecal samples were collected and 
cultured to confi rm the presence of  the challenge microorganism (ETEC K99+). Small 
intestines, jejunum and ileum were removed and sent to the Pathobiology Department 
at Ontario Veterinary College, University of  Guelph for examination.
Statistical analysis
Fisher’s Exact Probability statistical test was used to determine the signifi cance of  
mortality data. The One-way ANOVA analysis of  variance was used to determine the 
statistical signifi cance of  the clinical scores (diarrhea, behavior, milk consumption, 
duration and mortality) between the two groups. GraphPad Prism 6 statistical software 
(Santa Cruz, CA, USA) was used for all statistical analysis.
RESULTS
Adverse reactions
Following challenge with ETEC K99+ and treatment with MCWF, calves were 
monitored closely for two hours for any occurrence of  systemic or local reactions. 
Observations continued on a daily basis, three times a day for the entire duration of  
the study (seven days). There were no untoward reactions observed in any of  the 
calves given MCWF (data not shown).
Clinical observations
The zinc turbidity test (ZST) was performed twice (on arrival and 48h later) to 
determine if  passive transfer of  colostral IgG antibodies occurred. All calves tested 
negative for the presence of  colostral IgG antibodies at each test point (data not 
shown).
All calves were deemed healthy upon arrival as determined by physical examination. 
Eighteen to twenty-four hours post challenge with ETEC K99+, profuse watery to 
pasty, pale yellow to white, foul-smelling diarrhea, occasionally streaked with blood 
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fl ecks, was observed in all challenged calves. Defecation was frequent and effortless 
and the tail and perineum were soiled with faeces.
Faeces consistency and duration of diarrhea
Pens were cleaned daily and faeces consistency was scored on three occasions within 
the 24-hour period (morning, afternoon and evening). Faeces was scored on day 0, 
prior challenge, and then daily for the duration of  the study. First signs of  diarrhea 
occurred 18-24h (median of  18h) following challenge in all calves. Severity and 
duration of  diarrhea was signifi cantly reduced in the MCWF immunostimulant treated 
group compared to controls (Figure 1). Clinical scores related to faeces consistency 
were statistically signifi cant (p=0.03) between the two groups with mean faecal scores 
of  1.4 and 1.95 (Figure 1A) for MCWF and control group respectively. Furthermore, 
the mean duration of  diarrhea in untreated calves was 5.6 days compared to 4.3 days in 
MCWF group (Figure 1B). For the purpose of  data analysis on the duration of  diarrhea 
in challenged calves only results from surviving animals were taken into consideration. 
Even though there was no statistically signifi cant difference in the duration of  diarrhea 
between the two groups, there was an obvious biological and clinical difference in 
favor of  the MCWF group (duration of  diarrhea reduced by 1.3 days).
Hydration and behavior
Consistent with previous observation on E. coli K99+ induced diarrhea in neonatal 
calves, animals in the control group had a signifi cantly higher dehydration mean 
clinical score of  0.2 versus 0.04 (p=0.04) in the MCWF treated group (Figure 2A). 
Furthermore, mean behavioral (depression) scores were also reduced (0.46 versus 0.6) 
in the MCWF treated calves when compared to controls respectively; (Figure 2B).
Figure 1. Faecal consistency scores and mean duration of  diarrhea; a) Mean clinical scores for 
faecal consistency between the two groups (MCWF and control; *p=0.03); b) Mean clinical 
scores for duration of  diarrhea in calves between the two groups (MCWF and control; not 
statistically signifi cant (ns))
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Milk consumption and body weights
Milk consumption and body weights observations correlated with the course and 
pathogenesis characteristic of  E. coli infection in neonatal calves. Mean starting body 
weights for animals in both experimental groups were not signifi cantly different 
(Figure 3A). Animals in both experimental groups showed considerate body weight 
loss during the study (Figure 3A). Mean clinical body scores related to weight loss 
(Figure 3B) were lower in the MCWF group (mean score of  1.2 ) compared to the 
control group (mean score of  2). MCWF treated animals lost on average 4.2% (1.7 kg) 
Figure 2. Mean clinical scores for dehydration and behaviour; a) Mean clinical scores for 
dehydration between the two groups (MCWF and control; *p=0.04); b) Mean clinical scores 
for behaviour of  calves between the two groups (MCWF and control; not statistically signifi cant 
(ns)).
Figure 3. Mean scores for milk intake, body scores and body weights; a) Differences in 
body weights between the two groups (MCWF and control during the study; not statistically 
signifi cant (ns)); b) Mean body scores of  calves between the two groups (MCWF and control; 
not statistically signifi cant (ns)); c) Mean clinical scores related to milk intake between the two 
groups (MCWF and control; *p=0.02)
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of  their starting body weight while animals in the control group lost 6.9% (2.95 kg) of  
their starting body weight (Figure 3A). Four out of  ten animals in the MCWF group 
did not show any signs of  weight loss and had an average increase of  4.25% body 
weight at day seven compared to the control group in which only one animal showed 
increased body weight. Milk consumption results were in correlation with previous 
observations, where a lower milk intake was observed in the MCWF treated group 
(p=0.02) when compared to the control group (Figure 3B).
Body temperatures
Body temperatures were recorded upon arrival, prior to challenge and then during each 
scheduled daily observation. Slightly elevated body temperatures were observed at 12 
hours following challenge in all animals, but quickly returned to normal within 24 hours 
post-challenge. Body temperatures in the control group dropped below the normal 
value while no signifi cant changes in the MCWF group were observed (Figure 4).
Survival
To determine the survival rate following ETEC challenge, animals were monitored for 
a minimum of  seven days. As shown in Figure 5, the survival rate in the MCWF group 
was 90% (1 dead out of  10 animals), while survival rate in the control group was 42% 
(7 died out of  12 animals), which was statistically signifi cant at a 95% confi dence level 
(p<0.01). The average time of  death in the control group was 69.8 hours following 
challenge with the earliest occurrences at approximately 36-40 hours (3 deaths). One 
animal in the MCWF group died at 98 hours following challenge. Two animals from 
the control group were humanely euthanized as per protocol and CCAC guidance due 
to severe dehydration, diarrhea and decreased attitude. 
Figure 4. Body temperatures; Mean body temperatures of  calves in two groups (MCWF and 
control) during the course of  the study (seven days). Not statistically signifi cant (ns).
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Necropsy and bacterial culture
Consistent with previous observations related to infections of  neonatal calves with 
ETEC K99+ [19,20], the most dominant gross fi nding at necropsy was a mild to 
moderate catarrhal enteritis in the small intestines (ileum and jejunum). Dehydration 
of  carcasses and a white-yellowish fl uid in the intestines and smaller amounts of  
undigested milk were observed, as well. No other gross pathological fi ndings were 
found. On histopathology, a mild neutrophil infi ltration into the lamina propria 
and between the base of  the villi was found. Villi maintained their shape without 
signs of  atrophy, crypts were sorted properly and the surface epithelium was normal 
(Figure 6). These fi ndings were consistent with microscopic changes characteristic for 
enterotoxigenic colibacillosis [19, 20].
Figure 5. Survival rate; Survival rate in neonatal calves between the two groups during the 
course of  the study (MCWF= 90% and control=42%; *p<0.01) with the time of  death in both 
groups
Figure 6. Histopathology of  the small intestine; Hematoxylin-Eosin (HE) staining of  the 
representative sample of  small intestine (ileum) from one four-day old calf  that died due 
following ETEC K99+ infection. Magnifi cation 400x, scale bar at 100 μm.
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DISCUSSION
Neonatal calves are most susceptible to infection in the fi rst few hours of  life [2]. 
The pathogens most commonly incriminated in neonatal enteric infections include 
viral (Rotavirus and Coronavirus), protozoal (Cryptosporidium parvum) and bacterial 
pathogens (enterotoxigenic Escherichia coli K99+ and Salmonella spp.) [10,21,22]. Calf  
diarrhea induced by ETEC producing the K99+ adhesion antigen is still the most 
common microorganism isolated from diarrheic calves within the fi rst three days of  life 
[20,23]. The heat-stable enterotoxin produced by ETEC K99+ alters the functions of  
the enterocytes by increasing secretion and reducing absorption of  water, stimulating 
the release of  excessive liquid leading to the development of  a secretory (watery) 
diarrhea [19]. Consequently, depression, rapid weight loss, increased milk intake and 
mild to moderate mortality rate are observed causing signifi cant economic losses 
to the producers. Economic implications associated with ETEC diarrhea include 
increased investment and lower profi ts due to lower daily weight gains, increased 
costs of  treatment and higher numbers of  underweight or dead animals [20-22]. 
Cattle producers, particularly within the veal and beef  calf  industry are increasingly 
concerned with the high morbidity percentage and mortality among male calves which 
are removed from their dams within hours following birth. These calves receive no 
or minimal colostrum, and are exposed to signifi cant levels of  stress, including being 
shipped to auction barns or directly to veal operations. In most instances, these calves 
arrive at their fi nal destinations in poor health, already infected with one or multiple 
pathogens and without any supportive therapy. These calves have a diffi cult time 
adjusting to the new environment and usually show clinical signs of  enteric and/or 
respiratory diseases. In addition, they have diffi culties entering the regular production 
process, resulting in the immediate application of  supportive and metaphylactic 
treatments and added production costs. 
In this study, we aimed to mimic real-time conditions in terms of  early management 
of  newborn male calves and early exposure to one of  the most common pathogens, 
while testing an alternative to antibiotic therapy. The established challenge model was 
successful and consistent with ETEC pathogenesis and clinical symptoms in terms 
of  diarrhea onset, body temperatures, changes of  attitude and milk consumption 
as described previously [20,23]. In addition, pathomorphological observations 
on post mortem examination were consistent with ETEC infection described as 
mild to moderate dehydration and enterotoxicaemia contributing to a  moderate 
mortality rate [19,20]. The study results clearly demonstrated benefi cial effect of  
MCWF administration in colostrum deprived one to two day old calves challenged 
with ETEC K99+ as demonstrated by a reduced severity and duration of  diarrhea, 
reduced dehydration, lower behavior and food intake scores. Furthermore, animals in 
the MCWF group had a signifi cantly reduced loss of  body weight compared to the 
untreated controls with 4 animals in this group gaining up to 4% of  body weight since 
the start of  the study and pre-challenge.
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Preventive and treatment measures to reduce the morbidity and mortality associated 
with neonatal diarrhea include metaphylaxis with a variety of  antibiotics, combinations 
of  antibiotics and fl uids. However, the use of  antibiotics maybe costly and not 
applicable in all cow-calf  operations, particularly in organic certifi ed operations. The 
main disadvantage of  antibiotic therapy is its relationship to bacterial resistance and 
consequently increased health concern for both humans and animals. 
Compounds capable to elicit the immune response in the host, to either upregulate 
or downregulate specifi c events, are classifi ed as immunomodulators. MCWF contain 
immunomodulatory compounds such as trehalose 6,6′-dimycolate (TDM) and 
muramyl dipeptide (MDP) [24]. MDP enhances the expression of  surface markers 
on microorganisms that are necessary for cell adhesion and antigen presentation. 
This enhancement allows for an increase in phagocytosis, antimicrobial activity and 
antibody-mediated cytotoxicity [25-27]. Moreover, MDP has been shown to induce 
immune responses by increasing interferon gamma (IFN-γ) and other cytokine 
production and stimulating the production of  lymphocytes [28-30]. The TDM 
is a glycolipid component of  the mycobacterial cell wall that is found to be a non-
specifi c immunotherapeutic agent against cancer and infectious diseases [31]. TDM 
was also shown to stimulate macrophage activity [32] and enhance the production of  
interleukin 6 (IL-6) [33]. It is proposed that MCWF targets the calf ’s innate immune 
and cell-mediated immune responses in a similar manner, thus providing increased 
resistance to early infection and reduction of  associated clinical signs. MCWF has 
the ability to attract macrophages, neutrophils and initiate cytokine production in 
neonatal calves following intravenous, subcutaneous and intramuscular administration 
[34]. Data suggested that single MCWF administration, even in the high presence of  
cortisol, is suffi cient to trigger a strong innate and cell-mediated immune response 
as measured by IFN-γ, IL-2 and neutrophil infl ux and activation of  naïve CD4+ and 
CD8+ cells [34]. These data, accompanied with the current fi ndings on increased 
survival rate, reduced diarrhea and other clinical signs following challenge with ETEC 
K99+ provide suffi cient evidence that MCWF can be used as a novel therapeutic for 
ETEC treatment and potential antibiotic alternative.  Furthermore, our data suggested 
that if  MCWF is administered early in infection it can prevent or reduce economic 
losses due to increased food consumption, and less underweight or dead animals. In 
addition, early activation of  the neonate’s immune system could overcome the effects 
of  early infection and stress commonly seen in veal and baby beef  animals across 
North America. The use of  MCWF could provide a signifi cant health and cost benefi t 
to the farm management, particularly to organic farming operations where the use of  
antibiotics is prohibited. Additional studies are underway to explore further MCWF 
applications and application protocols, in order to improve the health status of  both 
cows and calves in small and large dairy and beef  operations.
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EFIKASNOST IMUNOSTIMULANTA (AMPLIMUNE™) 
POREKLOM OD FRAKCIJA MIKOBAKTERIJSKOG ĆELIJSKOG 
ZIDA U SMANJENJU INTENZITETA DIJAREJE NEONATALNE 
TELADI IZAZVANE SA ENTEROTOKSIČNOM Escherichia coli 
(ETEC) 
ROMANOWSKI Radoslaw, CULBERT Rick, ALKEMADE Stan, 
MEDELLIN-PEÑA Maira J., BUGARSKI Dejan, MILOVANOVIC Aleksandar, 
NESIC Sladjan, MASIC Aleksandar
Dijareja teladi je uobičajena bolest kod mladih životinja i primarni uzrok pada produk-
tivnosti i ekonomskih gubitaka u govedarskoj industriji širom sveta. Prema izveštaju 
National Animal Health Monitoring System Američke agencije za mleko, više od pede-
set procenata uginuća nezalučene teladi pripisuje se teškim prolivima. Enterotoksična 
Escherichia coli (ETEC) soj K99+ još uvek je najčešći patogen izolovan od teladi mlađih 
od tri dana starosti. Vakcinacija krava i upotreba antibiotika se i dalje najviše koriste 
kao metode prevencije i terapije dijareje teladi. Porast rezistencije mikroorganizama 
na antibiotike predstavlja i dalje veliku opasnost širom sveta što je i dovelo do razvoja 
istraživanja alternativnih terapija. Frakcije ćelijskog zida mikobakterija (MCWF) su 
biološki imunomodulator koji ima potencijal za upotrebu u više veterinarskih zdrast-
venih usluga kao što je lečenje i prevencija zaraznih bolesti i u onkologiji malih i velikh 
životinja. Efi kasnost MCWF u smanjenju mortaliteta povezanih sa neonatalnom dijar-
ejom teladi nakon ekperimentalne infekcije sa sojem ETEC K99+ je istraživan u ovom 
radu. Dvadeset i tri teleta su bila podeljena u dve eksperimentalne grupe. Jedanaest 
teladi je primilo jednu dozu MCWF od 1mL intravenski (IV) na početku pojave prvih 
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kliničkih znakova bolesti nakon infekcije. Dvanaest netretiranih, infi ciranih teladi su 
korišćeni kao kontrolna grupa. Intenzitet i trajanje dijareje su bili značajno smanjeni u 
grupi teladi tretiranih sa MCWF nakon poređenja sa ne tretiranom kontrolnom gru-
pom. Osim toga, smrtnost u MCWF tretiranoj grupi značajno je smanjena na 10%, 
dok je smrtnost u kontrolnoj grupi iznosila 58%. Podaci iz prikazanog ogleda ukazuju 
na to da se MCWF može koristiti kao alternativni tretman za smanjenje jačine, trajanja 
infekcije i mortaliteta neonatalne teladi  sa dijarejom, uzrokovanom ETEC.
